VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo proof-of-concept data and additional in vitro findings validating its BiTAC-ADC technology platform at the 17th World ADC Congress in San Diego. The announcement, made via NEWMEDIAWIRE, highlights a potential breakthrough in antibody-drug conjugate (ADC) design that could improve both efficacy and safety for cancer patients.
The in vivo study demonstrated significant tumor regression in a breast cancer model following a single 3 mg/kg dose, with no observed decrease in body weight. Notably, both BiTAC-ADC components were required to produce the intended tumor-specific response, underscoring the platform's precision. Additional in vitro studies showed the platform's ability to distinguish cancer cells from healthy cells, prevent the release of active toxins outside the tumor, and target multiple cancer cell lines. These findings support the potential of BiTAC-ADCs to deliver efficacy comparable to conventional ADCs while offering a differentiated safety profile designed to reduce systemic toxicity.
For investors and industry observers, these results are significant because they address a long-standing challenge in oncology: how to kill cancer cells without harming healthy tissue. Conventional ADCs often cause off-target toxicity due to premature release of cytotoxic payloads. The BiTAC-ADC platform appears to overcome this by requiring dual targeting, which may lead to better tolerability and a wider therapeutic window. If the platform continues to advance, it could become a cornerstone of next-generation cancer treatments, potentially improving patient outcomes and reducing side effects.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company's progress is closely watched, as evidenced by its inclusion in the VERAXA Biotech (NASDAQ: VRXA) profile on the Billion Dollar Club.
The full press release detailing these findings is available at https://ibn.fm/cs8SW, and investors can find the latest news and updates relating to VRXA in the company's newsroom at https://ibn.fm/VRXA. As with any forward-looking statements, actual results may differ materially due to risks and uncertainties, including those discussed in the company's SEC filings. Undue reliance should not be placed on such statements when making an investment decision.
